deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT01589302

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)

Sponsor: Kami Maddocks, MD

Conditions Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions Correlative laboratory samples ibrutinib quality of life assessment
Updated 17 times since 2017 Last updated: Jul 15, 2025 Started: May 21, 2012 Primary completion: Jul 28, 2016 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prolymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, this trial is ongoing. The trial is conducted by Kami Maddocks, MD and has accumulated 17 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Mar 2020 · 9 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2022 · 17 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Aug 2025 · 5 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded

  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Dec 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Apr 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kami Maddocks, MD
Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations